Recent advances in pharmacogenomics have opened new horizons in the personalized treatment of diabetic complications. By understanding how genetic variations influence individual responses to medications, healthcare providers can tailor therapies to improve efficacy and reduce adverse effects. This approach moves beyond the traditional one-size-fits-all model, offering the potential for better outcomes in a disease that affects hundreds of millions worldwide.

Diabetes mellitus, particularly type 2 diabetes, is associated with a wide range of complications including neuropathy, nephropathy, retinopathy, and cardiovascular disease. The burden of these complications drives significant morbidity and healthcare costs. Pharmacogenomics aims to address this by identifying genetic markers that predict drug response, thereby enabling clinicians to choose the right drug at the right dose for each patient. This article reviews the current state of pharmacogenomics in managing diabetic complications, highlighting key genetic variants, clinical implications, and future directions.

How Genetic Variations Shape Drug Response in Diabetes

Genetic polymorphisms in drug-metabolizing enzymes, transporters, and targets can dramatically alter pharmacokinetics and pharmacodynamics. Over the past decade, research has uncovered several clinically relevant variants that influence responses to common diabetes and cardiovascular medications.

Warfarin and CYP2C9 / VKORC1

Warfarin is widely used for anticoagulation in diabetic patients with atrial fibrillation or venous thromboembolism. Variants in CYP2C9 (which metabolizes warfarin) and VKORC1 (the target enzyme) affect dose requirements. Patients with CYP2C9 *2 or *3 alleles have reduced metabolism and require lower doses to avoid bleeding, while VKORC1 -1639G>A carriers are more sensitive to warfarin. The FDA-approved warfarin label includes pharmacogenetic dosing guidance, and studies in diabetic populations have confirmed that genotype-guided dosing reduces hospitalization rates for major bleeding and thromboembolism.

Sulfonylureas and TCF7L2

Sulfonylureas are insulin secretagogues commonly used in type 2 diabetes. Polymorphisms in TCF7L2 are strongly associated with type 2 diabetes risk and also modulate responses to sulfonylureas. Carriers of the risk allele (rs7903146) often show reduced glycemic improvement with sulfonylureas, possibly due to altered beta-cell function. In one large cohort, patients with the risk genotype had a 50% higher likelihood of requiring a switch to insulin within three years. This information can guide clinicians toward alternative agents such as metformin or GLP-1 receptor agonists in these patients.

Metformin and OCT1 / OCT2

Metformin remains the first-line oral agent for type 2 diabetes. Its absorption and renal excretion depend on organic cation transporters OCT1 (encoded by SLC22A1) and OCT2 (SLC22A2). Loss-of-function variants in SLC22A1 reduce metformin uptake into hepatocytes, leading to higher plasma concentrations and increased gastrointestinal side effects. Studies suggest that such patients may benefit from a lower starting dose or alternative therapy when intolerance develops. Similarly, variants in SLC22A2 affect renal clearance and can influence metformin efficacy. However, due to complex interplay, the clinical utility of routine OCT1/OCT2 genotyping remains a topic of active research.

Statins and SLCO1B1

Statins are essential for cardiovascular risk reduction in diabetes. The SLCO1B1 gene encodes OATP1B1, a hepatic transporter for statins. The rs4149056 variant (c.521T>C) is associated with reduced transport function, leading to increased plasma concentrations of simvastatin and a higher risk of myopathy. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend using lower doses of simvastatin or alternative statins (e.g., rosuvastatin, atorvastatin) in patients with one or two copies of the C allele. Given the high prevalence of diabetes and the frequent use of statins, this genetic test can prevent significant adverse events.

Pharmacogenomics in Specific Diabetic Complications

Beyond general diabetes management, pharmacogenomics offers opportunities to prevent and treat specific micro- and macrovascular complications.

Diabetic Neuropathy

Painful diabetic neuropathy affects approximately 20% of diabetic patients. First-line treatments include gabapentinoids, tricyclic antidepressants (TCAs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). Genetic variants in drug transporters and targets influence efficacy and toxicity. For example:

  • CYP2D6: This enzyme metabolizes many TCAs (e.g., nortriptyline) and some SNRIs. Poor metabolizers (about 7% of Caucasians) are at risk for elevated drug levels and cardiac toxicity, while ultra-rapid metabolizers may fail TCAs due to subtherapeutic levels. Genotype-guided dosing can optimize starting doses.
  • OPRM1: The A118G variant in the mu-opioid receptor affects pain perception and opioid requirements. In diabetic neuropathy patients, carriers of the G allele may have poorer response to tramadol, a prodrug also dependent on CYP2D6. Combining genotyping of both CYP2D6 and OPRM1 could guide opioid use and reduce the risk of dependence.
  • SCN9A: Variants in the voltage-gated sodium channel Nav1.7 have been linked to neuropathic pain susceptibility. Pharmacogenomic studies are exploring whether patients with gain-of-function SCN9A mutations derive greater benefit from sodium channel blockers like carbamazepine or lidocaine.

Diabetic Nephropathy

Diabetic nephropathy is the leading cause of end-stage renal disease. Two medication classes are cornerstone: renin-angiotensin-aldosterone system (RAAS) inhibitors (ACE inhibitors and ARBs) and SGLT2 inhibitors. Genetic variants can modify their renoprotective effects.

  • ACE I/D polymorphism: The ACE insertion/deletion (I/D) polymorphism influences circulating ACE levels and the response to ACE inhibitors. D allele carriers have higher ACE activity and may experience greater renoprotection from ACE inhibitors, though some studies show increased risk of cough and angioedema. Genotype-guided dosing of ACE inhibitors could maximize benefits.
  • KCNQ1: Variants near KCNQ1 (associated with type 2 diabetes risk) have been linked to the efficacy of SGLT2 inhibitors. Preliminary data suggest that certain haplotypes correlate with greater reductions in albuminuria and eGFR decline. While not yet routine, this could refine the choice among SGLT2 inhibitors, which differ in pharmacokinetics and transporter interactions.
  • PKM2: A recent genome-wide association study identified PKM2 variants as predictors of response to finerenone, a non-steroidal mineralocorticoid receptor antagonist shown to slow diabetic kidney disease. This exemplifies the emerging role of pharmacogenomics in newer therapies.

Diabetic Retinopathy

Diabetic retinopathy remains a leading cause of blindness. Intravitreal anti-VEGF agents (ranibizumab, aflibercept, bevacizumab) are mainstays, but response varies widely. Genetic factors influencing VEGF signaling and pharmacokinetics can explain some of this variability.

  • VEGFA: Polymorphisms in VEGFA (e.g., rs833061, rs2010963) affect VEGF expression. A meta-analysis found that carriers of certain alleles require fewer anti-VEGF injections to achieve dry macula and have better visual outcomes. Testing for these variants may help stratify patients into high-responder vs. low-responder groups, guiding the choice between ranibizumab and aflibercept.
  • CFH: The CFH Y402H variant, known for age-related macular degeneration risk, has also been linked to anti-VEGF response in diabetic macular edema. Patients with the risk allele may experience persistent edema despite treatment, suggesting a potential benefit from combination therapy with corticosteroids.
  • Transporter genes: ABCB1 (P-glycoprotein) variants can affect intravitreal clearance of anti-VEGF agents. Studies are ongoing to determine whether patients with efflux transporter variants require more frequent injections or higher doses.

Clinical Implementation: From Bench to Bedside

Despite robust evidence for several gene–drug pairs, the translation of pharmacogenomics into routine diabetes care faces practical hurdles.

Key Challenges

  • Cost and reimbursement: Genetic testing panels can cost hundreds of dollars. While some insurers cover testing for warfarin or HLA-B*5701 (for abacavir), broader pharmacogenomic panels are not uniformly reimbursed. Economic studies are needed to demonstrate cost-effectiveness in diabetic populations.
  • Clinical workflow integration: Results must be available at the point of prescribing. Preemptive genotyping (testing before drugs are needed) is gaining traction, but requires electronic health record (EHR) alerts and decision support. The multi-gene impact across many drugs demands sophisticated clinical decision support (CDS) tools that can interpret multiple genotypes simultaneously.
  • Provider education: Many clinicians lack confidence in interpreting pharmacogenomic results. Continuing medical education programs and updated guidelines (CPIC, FDA labeling) help, but a survey found that only 20% of physicians felt prepared to use pharmacogenomic data for prescribing. Embedding CDS into EHRs with actionable recommendations can bridge this gap.
  • Diverse populations: Most pharmacogenomic studies have been in European-derived populations. Variants common in other ancestries (e.g., CYP2C9 *5, *6, *8, *11 in African populations) are understudied, limiting generalizability. Initiatives like the All of Us Research Program and H3Africa are addressing this, but more inclusive data are urgently needed.

Model Programs and Available Resources

Several institutions have implemented preemptive pharmacogenomic programs. The University of Florida Health Personalized Medicine Program and the eMERGE Network provide templates for integrating testing with EHR alerts. For diabetic prescribing, these programs often include:

  • Panel-based testing covering CYP2C9 + VKORC1 for warfarin, SLCO1B1 for statins, and CYP2D6 for TCAs and opioids.
  • Automated drug–gene interaction alerts at order entry.
  • Access to a pharmacist genomics specialist for complex cases.

Patients can benefit from direct-to-consumer genetic tests (e.g., 23andMe provides SLCO1B1, CYP2C9, and VKORC1 reports), but clinical interpretation is essential. The NIH Pharmacogenomics Knowledgebase (PharmGKB) provides curated guidelines and dosing recommendations, and the CPIC website offers downloadable algorithms. For example, CPIC guidelines for CYP2C9 and VKORC1 provide a table of starting warfarin doses based on genotype, which has been validated in diabetic populations.

Future Directions: Polygenic Risk Scores and Drug Development

The next frontier is integrating polygenic risk scores (PRS) with pharmacogenomics. A PRS for diabetic complications (e.g., a PRS for nephropathy or cardiovascular risk) could identify patients who need more aggressive therapy with specific agent classes. For example, a patient with a high PRS for diabetic nephropathy might preferentially receive an SGLT2 inhibitor and a RAAS inhibitor, while a high cardiovascular PRS might favor a GLP-1 receptor agonist. Combining PRS with pharmacogenomic markers could create a truly individualized therapeutic algorithm.

Drug development is also evolving. Pharmaceutical companies are using pharmacogenomic data to enrich clinical trials with likely responders, reducing costs and improving success rates. For instance, a new agent for diabetic neuropathic pain might be tested only in patients with a specific SCN9A or OPRM1 genotype. This approach is already common in oncology and is gaining traction in metabolic diseases.

Emerging technologies such as long-read sequencing and liquid biopsies may enable point-of-care genetic testing for multiple genes simultaneously in a single blood draw, making pharmacogenomics accessible in primary care. In addition, artificial intelligence models trained on large EHR-linked biobanks can predict drug response and adverse events without requiring explicit genotyping by using inferred genotypes from imputation or even clinical features, though direct genotyping remains preferred.

Conclusion

Pharmacogenomics has moved from discovery to implementation for several drugs used to manage diabetic complications. Variants in CYP2C9, VKORC1, SLCO1B1, and TCF7L2 have clear clinical utility, while emerging markers for neuropathy, nephropathy, and retinopathy hold promise for even more personalized care. Challenges remain in cost, workflow, education, and diversity, but model programs and updated guidelines are paving the way. As genetic testing becomes cheaper and more integrated into EHRs, the vision of truly personalized treatment for diabetic complications will increasingly become a standard of care, reducing the global burden of this devastating disease.

Additional Resources